We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
-8.25%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$3.75B
AUM Growth
-$833M
(-18%)
Cap. Flow
-$27.3M
Cap. Flow
% of AUM
-0.73%
Top 10 Holdings %
Top 10 Hldgs %
47.18%
Holding
110
New
14
Increased
9
Reduced
11
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veru
VERU
|
+$91.7M |
| 2 |
PepGen
PEPG
|
+$90.7M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$66.8M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$36.2M |
| 5 |
Nkarta
NKTX
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$60.4M |
| 2 |
MacroGenics
MGNX
|
+$53.8M |
| 3 |
Novavax
NVAX
|
+$51M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$32.1M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.19% |
| 2 | Financials | 1.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TERN
76
DELISTED
Terns Pharmaceuticals
TERN
| $3.13M | 0.08% |
+1,261,435
| New | +$2.52M |
|
77
BioAtla
BCAB
$5.46M
| $2.94M | 0.08% |
+20,636
| New | +$3.28M |
|
|
ATXS
78
DELISTED
Astria Therapeutics
ATXS
| $2.28M | 0.06% |
760,857
-501,336
| -40% | -$2.25M |
|
79
Pyxis Oncology
PYXS
$168M
| $2.27M | 0.06% |
953,393
-1,328,780
| -58% | -$3.54M |
|
|
ADVM
80
DELISTED
Adverum Biotechnologies
ADVM
| $2.07M | 0.06% |
+172,602
| New | +$1.81M |
|
81
Larimar Therapeutics
LRMR
$397M
| $2.02M | 0.05% |
1,031,482
-250,378
| -20% | -$740K |
|
|
ORTX
82
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $1.78M | 0.05% |
304,089
-665,390
| -69% | -$3.75M |
|
83
CVRx
CVRX
$137M
| $1.65M | 0.04% |
275,000
| – | – |
|
|
FTH
84
Faeth Therapeutics
FTH
$702M
| $1.64M | 0.04% |
+36,177
| New | +$1.36M |
|
85
Olema Pharmaceuticals
OLMA
$1B
| $952K | 0.03% |
233,793
-270,712
| -54% | -$859K |
|
86
Bolt Biotherapeutics
BOLT
$7.67M
| $918K | 0.02% |
+22,507
| New | +$874K |
|
|
TECX
87
Tectonic Therapeutic
TECX
$529M
| $515K | 0.01% |
+46,633
| New | +$550K |
|
88
Lisata Therapeutics
LSTA
$9.02M
| $399K | 0.01% |
+50,167
| New | +$413K |
|
89
Cullinan Oncology
CGEM
$1.01B
| – | – |
-350,000
| Closed | -$3.67M |
|
90
Compass Therapeutics
CMPX
$344M
| – | – |
-532,958
| Closed | -$730K |
|
|
CNTA
91
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-3,577,094
| Closed | -$32.1M |
|
92
Edgewise Therapeutics
EWTX
$4.13B
| – | – |
-2,613,623
| Closed | -$25.4M |
|
93
KALA BIO
KALA
$14.1M
| – | – |
-4,354
| Closed | -$15M |
|
|
KALV
94
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-1,930,322
| Closed | -$28.5M |
|
|
95
MacroGenics
MGNX
$235M
| – | – |
-6,103,594
| Closed | -$53.8M |
|
|
96
Novavax
NVAX
$1.2B
| – | – |
-692,794
| Closed | -$51M |
|
|
SCPH
97
DELISTED
scPharmaceuticals
SCPH
| – | – |
-2,658,583
| Closed | -$15.1M |
|
98
TScan Therapeutics
TCRX
$48.6M
| – | – |
-1,021,764
| Closed | -$2.86M |
|
99
Tango Therapeutics
TNGX
$4.43B
| – | – |
-2,250,000
| Closed | -$17.1M |
|
|
VERV
100
DELISTED
Verve Therapeutics
VERV
| – | – |
-310,284
| Closed | -$7.08M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, RA Capital Management held 110 positions worth $3.75B, down 18% from $4.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
RA Capital Management's Q2 2022 filing shows 14 new, 9 increased, 11 reduced and 22 closed positions. Its largest new stake was Veru: 790,000 shares worth $89.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $60.4M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.
- RA Capital Management's largest Q2 2022 buy was Veru: 790,000 shares worth $89.3M.
- RA Capital Management added most to Aclaris Therapeutics in Q2 2022, an estimated $36.2M increase.
- RA Capital Management's biggest Q2 2022 reduction was LianBio American Depositary Shares, cutting an estimated $10.3M.
- RA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $60.4M.
- RA Capital Management's ten largest holdings make up 47% of its $3.75B portfolio in Q2 2022.
- RA Capital Management opened 14 new positions and closed 22 in Q2 2022.
- RA Capital Management's portfolio value fell 18% quarter-over-quarter to $3.75B.
Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.